SCHEMBL22658415

SCHEMBL22658415

[2H]c1c([N+](=O)[O-])c([2H])c2oc(CC)c(C(=O)c3cc(Br)c(O)c(Br)c3)c2c1[2H]

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC22A12 Q96S37 10/20 0.56
▸ TTR P02766 6/20 0.56
▸ EYA3 Q99504 4/20 0.56
▸ CYP2C19 P33261 4/20 0.56
▸ CYP2C9 P11712 3/20 0.56
▸ PTPN1 P18031 3/20 0.56
▸ MEN1 O00255 2/20 0.56
▸ ABCB11 O95342 2/20 0.56
▸ LMNA P02545 2/20 0.56
▸ PGR P06401 2/20 0.56
▸ ADRA2A P08913 2/20 0.56
▸ TBXA2R P21731 2/20 0.56
▸ OPRM1 P35372 2/20 0.56
▸ SLC6A3 Q01959 2/20 0.56
▸ KMT2A Q03164 2/20 0.56
▸ EYA2 O00167 1/20 0.56
▸ ABCC4 O15439 1/20 0.56
▸ PLIN1 O60240 1/20 0.56
▸ NR1I2 O75469 1/20 0.56
▸ USP2 O75604 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22658416 0.85 SLC22A12 (0.65) SLC22A12TTREYA3CYP2C19CYP2C9
SCHEMBL22658414 0.83 SLC22A12 (0.61) SLC22A12TTREYA3CYP2C19CYP2C9
SCHEMBL25815049 0.82 SLC22A12 (0.71) SLC22A12TTREYA3CYP2C19CYP2C9
Benzbromarone SCHEMBL22658405 0.81 SLC22A12 (0.67) SLC22A12TTREYA3CYP2C19CYP2C9
SCHEMBL22658417 0.81 SLC22A12 (0.58) SLC22A12TTREYA3CYP2C19CYP2C9
SCHEMBL30527219 0.79 SLC22A12 (0.57) SLC22A12TTREYA3CYP2C19CYP2C9
SCHEMBL22658413 0.77 SLC22A12 (0.53) SLC22A12TTREYA3CYP2C19CYP2C9
SCHEMBL22072730 0.74 SLC22A12 (0.88) SLC22A12TTREYA3CYP2C19CYP2C9
Benzbromarone SCHEMBL48993 0.73 SLC22A12 (1.00) SLC22A12TTREYA3CYP2C19CYP2C9
Benzbromarone SCHEMBL19205474 0.73 SLC22A12 (1.00) SLC22A12TTREYA3CYP2C19CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116648445-A Methods for treating or preventing chronic kidney disease 安索治疗公司 2023-08-25 — — CN disclosed
US-20230218563-A1 METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE ARTHROSI THERAPEUTICS, INC. 2023-07-13 — — US disclosed
EP-4164624-A1 METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE Arthrosi Therapeutics, Inc. (US) 2023-04-19 — — EP disclosed
US-20220242841-A1 COMPOUND FOR TREATING GOUT OR HYPERURICEMIA ARTHROSI THERAPEUTICS, INC. 2022-08-04 — — US disclosed
EP-3968989-A1 COMPOUND FOR TREATING GOUT OR HYPERURICEMIA Arthrosi Therapeutics, Inc. (US) 2022-03-23 — — EP disclosed
WO-2021252630-A1 METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE ARTHROSI THERAPEUTICS, INC. (US) 2021-12-16 — — WO disclosed
WO-2020232156-A1 COMPOUND FOR TREATING GOUT OR HYPERURICEMIA ARTHROSI THERAPEUTICS, INC. (US) 2020-11-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220242841-A1 COMPOUND FOR TREATING GOUT OR HYPERURICEMIA CYP27A1, CYP27B1, XDH SLC22A12 564/4885TTR 380/4885EYA3 4415/4885
US-20230218563-A1 METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE ATP6V1B1, REN, CYP27B1 SLC22A12 620/4885TTR 201/4885EYA3 3141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback